Stonepine Capital Management LLC Makes New $3.68 Million Investment in Inhibikase Therapeutics, Inc. (NYSE:IKT)

Stonepine Capital Management LLC purchased a new stake in shares of Inhibikase Therapeutics, Inc. (NYSE:IKT) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 1,132,388 shares of the company’s stock, valued at approximately $3,680,000. Inhibikase Therapeutics comprises approximately 3.0% of Stonepine Capital Management LLC’s holdings, making the stock its 12th biggest position. Stonepine Capital Management LLC owned 1.63% of Inhibikase Therapeutics as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also recently made changes to their positions in IKT. OMERS ADMINISTRATION Corp purchased a new stake in shares of Inhibikase Therapeutics during the fourth quarter valued at $177,000. Millennium Management LLC purchased a new position in Inhibikase Therapeutics in the 4th quarter worth about $462,000. Jefferies Financial Group Inc. bought a new position in Inhibikase Therapeutics during the 4th quarter valued at about $48,000. Fairmount Funds Management LLC purchased a new stake in shares of Inhibikase Therapeutics during the 4th quarter valued at about $19,906,000. Finally, Blackstone Inc. purchased a new stake in shares of Inhibikase Therapeutics during the 4th quarter valued at about $6,730,000. Hedge funds and other institutional investors own 3.81% of the company’s stock.

Inhibikase Therapeutics Price Performance

IKT stock opened at $2.01 on Friday. Inhibikase Therapeutics, Inc. has a 1 year low of $1.12 and a 1 year high of $4.20. The company has a market cap of $149.43 million, a P/E ratio of -0.75 and a beta of 1.01. The stock’s fifty day moving average price is $2.11 and its 200-day moving average price is $2.49.

Wall Street Analyst Weigh In

Separately, HC Wainwright reissued a “neutral” rating on shares of Inhibikase Therapeutics in a report on Friday, March 28th.

Inhibikase Therapeutics Profile

Inhibikase Therapeutics, Inc, a clinical-stage pharmaceutical company, develops therapeutics for Parkinson’s disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson’s disease and gastrointestinal tract.